Sofia Fund Focus on Women-Led Firms

Interview with Neal St Anthony of the Star Tribune brings visibility to Sofia Fund and its partners’ long and successful involvement in investing in women led companies. Sofia Fund Partners Maintain Their Focus on Women-Led...

Looking Concussion in the Eye

A recent post in the April/ May Issue of MIT Review discusses the science Uzma Samadani used as she sought to find a way to measure improvements in her severely, brain-injured patients.   The ability to capture a large amount of data from tracking not only eye movement but restrictions on range of motion in the eye led to the EyeBox product being developed by Oculogica, one of Sofia Fund’s portfolio companies.   Eye tracking has been used for centuries but measuring and interpreting the restrictions on the range of motion without a baseline measurement is helping take the guesswork out of  diagnosing and tracking improvements in concussed patients.   See more at  Looking Concussion in the Eye...

Sofia Fund Invests in Joylux, Inc

SOFIA FUND ANNOUNCES INVESTMENT IN HEALTH TECHNOLOGY COMPANY JOYLUX   MAY 3, 2018 (Minneapolis) — Sofia Fund, a leading angel investment firm focused on high-growth, women-led early stage companies, today announced it has invested in Joylux, Inc., the Seattle-based women’s intimate health and wellness company. The Sofia Fund investment was part of Joylux’s recent Series A financing round, which closes Aug. 31, 2018, through which the company has raised $5 million. The funding will support Joylux’s launch of its vFit product in the U.S. Designed with postpartum and postmenopausal women in mind, the product is the first noninvasive, hormone-free intimate wellness solution for home use that incorporates a patented combination of red light (LED), gentle heat and sonic technology. “With more women entrepreneurs growing successful companies, demand for funding is the highest we’ve ever seen; we’re reviewing up to 150 companies each year,” said Lisa Crump, managing partner of Sofia Fund. “We focus on businesses with compelling value propositions and innovative technology that addresses significant market needs. Joylux has both of these advantages.” Joylux research indicates that 95 percent of the women it studied had a need to feel more confident during intimacy which is, many times, compromised after childbirth or menopause. “I’ve spent my career working with advanced technologies and developing products for aesthetics. After the birth of my son, I discovered there was a lack of product innovation in pelvic floor health, so I applied the same scientific principles used in advanced aesthetics to the vFit solution,” said Colette Courtion. The vFit is currently sold at www.getvfit.com, and the vFit PLUS professional model is available exclusively through physicians’...

Sofia Fund Achieves Exit

Rebiotix, Inc., Announces Its Acquisition   APRIL 9, 2018 (Minneapolis) — Sofia Fund, a leading angel investment firm focused on high-growth, women-led early stage companies, today announced that its portfolio company, Rebiotix, Inc., is being acquired by Ferring Holding, Inc., a U.S.-based subsidiary of Ferring Pharmaceuticals, a Swiss-based, privately-held, biopharmaceutical company.  Rebiotix is a microbiome company and will become the Microbiome Center of Excellence for Ferring, retain the Rebiotix name, and operate as a wholly owned subsidiary. Sofia Fund held investments in Rebiotix in both Sofia Fund and Sofia Fund II. For investors in the first Sofia Fund, this is the third exit from their original portfolio of nine companies. This is the first exit for Sofia Fund II, which started investing in 2015. The exit will provide a positive return to investors in both funds with additional payouts based on performance milestones of Rebiotix. “This is an exciting transaction for the women-led entrepreneurial community as one of its role models, serial entrepreneur and Rebiotix President and CEO Lee Jones, leads the company into its next stage,” said Joy Lindsay, Sofia Fund managing partner. “This development further reinforces the fact that women-led companies, often overlooked by venture capitalists, continue to grow exciting, successful businesses with compelling value propositions and innovative products that address significant market needs.” “Sofia Fund was one of our earliest investors,” said Jones, whose experience includes leading Inlet Medical, where she led its turnaround to profitability and ultimate sale. “Sofia Fund managing partners have deep experience in recognizing the potential of early stage companies, having invested in more than 50 companies over the course of 30...

Sofia Fund Makes Third Investment in Cognition Therapeutics

Sofia Fund recently announced its third investment in Cognition Therapeutics, Inc. (CogRx), a Pittsburgh-based biopharmaceutical company that discovers, develops and manufactures innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders. The Sofia Fund investment was part of Cognition Therapeutic’s most recent financing round, through which the company hopes to raise up to $5 million. “CogRx continues to hit its milestones, which are significant advancements in the development of breakthrough drugs that protect synapses, stopping the memory loss associated with Alzheimer’s disease,” said Cathy Connett, managing partner of Sofia Fund, and a 25-year angel investor in early stage companies, particularly those that are women-led. “We believe in the value proposition of the company. Its products address a significant problem – the threat of Alzheimer’s – that affects a large population: five million people in the U.S. alone currently live with the disease.”  Connett adds that the investment team at Sofia Fund also recognized the strength of the company’s diverse leadership team and its vision. “Sofia Fund has been a strong funding partner from the start,” said Cognition Therapeutics Chief Science Officer Dr. Susan Catalano, who co-founded the company in 2007. “This investment in our research comes at a critical time. We are about to begin key clinical trials with Elayta™ (CT1812) in Alzheimer’s disease patients in the United States. Alzheimer’s is the sixth-leading cause of death in this country, killing more people each year than breast and prostate cancer combined.” Cognition is focused on advancing the development of Elayta, an experimental medicine that is designed to protect synapses from one of the toxic proteins that causes Alzheimer’s...